UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 322

Sortiert nach

Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial

Annals of oncology, 2019-05, Vol.30 (5), p.788-795

2019

Volltextzugriff (PDF)

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients

Annals of oncology, 2018-04, Vol.29 (4), p.1037-1048

2018

Volltextzugriff (PDF)

Manipulation of a quasi-natural cell block for high-efficiency transplantation of adherent somatic cells

Brazilian journal of medical and biological research, 2015-05, Vol.48 (5), p.392-400

2015

Volltextzugriff (PDF)

294 Heat Shock Protein-90 (Hsp-90) Inhibitor, 17-AAG Blocks Transforming Growth Factor (TGF)-β1 Induced Epithelialmesenchymal Transition (EMT) in A549 Cells

European journal of cancer (1990), 2012-11, Vol.48, p.90-90

2012

Volltextzugriff (PDF)

2318 Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

European journal of cancer (1990), 2015-09, Vol.51, p.S438-S439

2015

Volltextzugriff (PDF)

Extracapsular spread and FDG PET/CT correlations in oral squamous cell carcinoma

International journal of oral and maxillofacial surgery, 2013-02, Vol.42 (2), p.158-163

2013

Volltextzugriff (PDF)

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

European journal of cancer (1990), 2015-09, Vol.51, p.S446-S446

2015

Volltextzugriff (PDF)

2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies

European journal of cancer (1990), 2015-09, Vol.51, p.S458-S458

2015

Volltextzugriff (PDF)

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

Journal of hepatology, 2016, Vol.64 (2), p.S693-S694

2016

Volltextzugriff (PDF)

Grain refinement, thermal stability and tensile properties of 2024 aluminum alloy after equal-channel angular pressing

Journal of materials processing technology, 2005-02, Vol.159 (3), p.314-320

2005

Volltextzugriff (PDF)

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

Annals of oncology, 2021-03, Vol.32 (3), p.368-374

2021

Volltextzugriff (PDF)

1035P Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors

Annals of oncology, 2023-10, Vol.34, p.S629-S629

2023

Volltextzugriff (PDF)

97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)

Annals of oncology, 2023-10, Vol.34, p.S216-S216

2023

Volltextzugriff (PDF)

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

Annals of oncology, 2017-03, Vol.28 (3), p.547-554

2017

Volltextzugriff (PDF)

133MO Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966

Annals of oncology, 2023-11, Vol.34, p.S1523

2023

Volltextzugriff (PDF)

Digital 3-Dimensional Liver Model Aids In Surgical Planning For Liver Tumors

HPB (Oxford, England), 2020, Vol.22, p.S44-S45

2020

Volltextzugriff (PDF)

100P Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)

Annals of oncology, 2023-10, Vol.34, p.S218-S218

2023

Volltextzugriff (PDF)

102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study

Annals of oncology, 2023-10, Vol.34, p.S220-S220

2023

Volltextzugriff (PDF)

69P PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer

Annals of oncology, 2020-09, Vol.31, p.S267-S267

2020

Volltextzugriff (PDF)

91P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

Annals of oncology, 2022-11, Vol.33, p.S1470-S1470

2022

Volltextzugriff (PDF)

57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

Annals of oncology, 2022-09, Vol.33, p.S566-S567

2022

Volltextzugriff (PDF)

490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)

Annals of oncology, 2022-09, Vol.33, p.S764-S765

2022

Volltextzugriff (PDF)

595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

Annals of oncology, 2023-11, Vol.34, p.S1702-S1703

2023

Volltextzugriff (PDF)

97P Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)

Annals of oncology, 2023-11, Vol.34, p.S1508-S1509

2023

Volltextzugriff (PDF)

1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

Annals of oncology, 2023-10, Vol.34, p.S756-S757

2023

Volltextzugriff (PDF)

1 – 25 von 322

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(271)
Mit Volltextzugriff
(299)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(175)
Life Sciences & Biomedicine
(106)
Physical Sciences
(55)
Humans
(46)
Biological And Medical Sciences
(45)
Technology
(41)
Physics
(38)
Male
(36)
Female
(33)
Fundamental And Applied Biological Sciences. Psychology
(32)
Animals
(26)
Adult
(25)
Exact Sciences And Technology
(21)
Materials Science
(21)
Medical Sciences
(20)
Microbiology
(19)
Engineering
(17)
Middle Aged
(17)
Chemistry
(16)
Oncology
(15)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients

Manipulation of a quasi-natural cell block for high-efficiency transplantation of adherent somatic cells

294 Heat Shock Protein-90 (Hsp-90) Inhibitor, 17-AAG Blocks Transforming Growth Factor (TGF)-β1 Induced Epithelialmesenchymal Transition (EMT) in A549 Cells

2318 Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer

Extracapsular spread and FDG PET/CT correlations in oral squamous cell carcinoma

2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment

2365 Nanoliposomal irinotecan (MM-398, nal-IRI) population pharmacokinetics (PK) and its association with efficacy and safety in patients with solid tumors based on the phase 3 study NAPOLI-1 and five phase 1 and 2 studies

Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade

Grain refinement, thermal stability and tensile properties of 2024 aluminum alloy after equal-channel angular pressing

A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial

1035P Phase I dose escalation study of IMC-002, a novel anti-CD47 monoclonal antibody, in patients with advanced solid tumors

97P Neoadjuvant durvalumab plus gemcitabine and cisplatin (D+GemCis) versus gemcis alone for localized biliary tract cancer (BTC): Results of a randomized, multicenter, open-label, phase II trial (DEBATE)

Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition

133MO Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC): Updated efficacy and safety from KEYNOTE-966

Digital 3-Dimensional Liver Model Aids In Surgical Planning For Liver Tumors

100P Hepatitis B virus (HBV)-related outcomes in patients (pts) with baseline HBV infection in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC)

102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study

69P PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer

91P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)

595P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

97P Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)

1315MO Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC)

Suchergebnisse filtern